At last, a win for terlipressin -- and Mallinckrodt

Ten years after being rebuffed by FDA and with a failed Phase III trial squeezed in between, Mallinckrodt’s terlipressin finally hit the mark in treating patients with an acute form of kidney failure.

On Thursday, the specialty pharma said terlipressin met the primary endpoint of

Read the full 440 word article

User Sign In